Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental).
Aged
Anxiety Disorders
/ epidemiology
Biological Psychiatry
/ methods
Comorbidity
Depressive Disorder, Major
/ epidemiology
Expert Testimony
/ methods
Female
Foundations
/ standards
France
/ epidemiology
Humans
Male
Personality Disorders
/ epidemiology
Practice Guidelines as Topic
/ standards
Psychiatry
/ standards
Psychopharmacology
/ methods
Substance-Related Disorders
/ epidemiology
Anxiety disorders
Elderly
Major depressive disorder
Pharmacotherapy
Substance use disorders
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
30 01 2019
30 01 2019
Historique:
received:
07
08
2018
accepted:
11
01
2019
entrez:
1
2
2019
pubmed:
1
2
2019
medline:
20
11
2019
Statut:
epublish
Résumé
Recommendations for pharmacological treatments of major depression with specific comorbid psychiatric conditions are lacking. The French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of depression based on the RAND/UCLA Appropriatneness Method. Recommendations for lines of treatment are provided by the scientific committee after data analysis and interpretation of the results of a survey of 36 psychiatrist experts in the field of major depression and its treatments. The expert guidelines combine scientific evidence and expert clinician's opinion to produce recommendations for major depression with comorbid anxiety disorders, personality disorders or substance use disorders and in geriatric depression. These guidelines provide direction addressing common clinical dilemmas that arise in the pharmacologic treatment of major depression with comorbid psychiatric conditions.
Sections du résumé
BACKGROUND
Recommendations for pharmacological treatments of major depression with specific comorbid psychiatric conditions are lacking.
METHOD
The French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of depression based on the RAND/UCLA Appropriatneness Method. Recommendations for lines of treatment are provided by the scientific committee after data analysis and interpretation of the results of a survey of 36 psychiatrist experts in the field of major depression and its treatments.
RESULTS
The expert guidelines combine scientific evidence and expert clinician's opinion to produce recommendations for major depression with comorbid anxiety disorders, personality disorders or substance use disorders and in geriatric depression.
CONCLUSION
These guidelines provide direction addressing common clinical dilemmas that arise in the pharmacologic treatment of major depression with comorbid psychiatric conditions.
Identifiants
pubmed: 30700272
doi: 10.1186/s12888-019-2025-7
pii: 10.1186/s12888-019-2025-7
pmc: PMC6354367
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Références
Am J Geriatr Psychiatry. 2002 Sep-Oct;10(5):541-50
pubmed: 12213688
Can J Psychiatry. 2016 Sep;61(9):540-60
pubmed: 27486148
Depress Anxiety. 2007;24(7):487-94
pubmed: 17177199
World J Psychiatry. 2015 Dec 22;5(4):366-78
pubmed: 26740928
Eur Psychiatry. 1999 Apr;14(2):101-6
pubmed: 10572334
Ann Pharmacother. 2007 Oct;41(10):1583-92
pubmed: 17848424
J Clin Psychiatry. 1993 Jan;54 Suppl:20-3
pubmed: 8093885
Encephale. 2013 Dec;39 Suppl 4:189-203
pubmed: 24373464
J Affect Disord. 2012 Jul;139(2):172-80
pubmed: 22381955
J Psychopharmacol. 2015 May;29(5):459-525
pubmed: 25969470
J Clin Psychopharmacol. 2005 Dec;25(6):580-3
pubmed: 16282842
Int J Psychiatry Clin Pract. 2004;8(4):205-11
pubmed: 24930548
J Affect Disord. 2005 May;86(1):99-104
pubmed: 15820277
Clin Geriatr Med. 2014 Aug;30(3):517-34
pubmed: 25037293
Ther Adv Psychopharmacol. 2016 Apr;6(2):99-144
pubmed: 27141292
J Clin Psychiatry. 1998 Mar;59(3):123-7
pubmed: 9541155
J Clin Psychopharmacol. 2011 Dec;31(6):763-8
pubmed: 22020357
Acta Psychiatr Scand. 2005 Dec;112(6):425-33
pubmed: 16279871
World J Biol Psychiatry. 2013 Jul;14(5):334-85
pubmed: 23879318
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
J Affect Disord. 2017 Aug 15;218:217-226
pubmed: 28477500
JAMA Psychiatry. 2017 Aug 1;74(8):853
pubmed: 28636715
J Affect Disord. 2005 Jul;87(1):43-55
pubmed: 15894381
Dialogues Clin Neurosci. 2015 Jun;17(2):181-90
pubmed: 26246792
Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45
pubmed: 10767867
Depress Anxiety. 2004;19(2):121-6
pubmed: 15022147
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
J Clin Psychiatry. 1999 Jul;60(7):446-8
pubmed: 10453798
J Addict Behav Ther Rehabil. 2016;5(4):
pubmed: 28393081
Br J Psychiatry. 2006 Jan;188:13-20
pubmed: 16388064
Psychiatr Ann. 2008 Nov 1;38(11):nihpa128505
pubmed: 19668349
Depress Anxiety. 2002;16(4):162-71
pubmed: 12497648
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
Compr Psychiatry. 1983 May-Jun;24(3):278-84
pubmed: 6347516
J Clin Psychiatry. 2005;66 Suppl 8:22-9
pubmed: 16336033
Psychopharmacol Bull. 2003 Spring;37 Suppl 1:76-88
pubmed: 14566203
BMJ Open. 2018 Sep 5;8(9):e022170
pubmed: 30185574